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Abstract
Objectives The 2019 Lung CT Screening Reporting & Data System version 1.1 (Lung-RADS v1.1) introduced volumetric
categories for nodule management. The aims of this study were to report the distribution of Lung-RADS v1.1 volumetric
categories and to analyse lung cancer (LC) outcomes within 3 years for exploring personalized algorithm for lung cancer
screening (LCS).
Methods Subjects from the Multicentric Italian Lung Detection (MILD) trial were retrospectively selected by National Lung
Screening Trial (NLST) criteria. Baseline characteristics included selected pre-test metrics and nodule characterization according
to the volume-based categories of Lung-RADS v1.1. Nodule volume was obtained by segmentation with dedicated semi-
automatic software. Primary outcome was diagnosis of LC, tested by univariate and multivariable models. Secondary outcome
was stage of LC. Increased interval algorithms were simulated for testing rate of delayed diagnosis (RDD) and reduction of low-
dose computed tomography (LDCT) burden.
Results In 1248 NLST-eligible subjects, LC frequency was 1.2% at 1 year, 1.8% at 2 years and 2.6% at 3 years. Nodule volume
in Lung-RADS v1.1 was a strong predictor of LC: positive LDCT showed an odds ratio (OR) of 75.60 at 1 year (p < 0.0001), and
indeterminate LDCT showed an OR of 9.16 at 2 years (p = 0.0068) and an OR of 6.35 at 3 years (p = 0.0042). In the first 2 years
after negative LDCT, 100% of resected LC was stage I. The simulations of low-frequency screening showed a RDD of 13.6–
21.9% and a potential reduction of LDCT burden of 25.5–41%.
Conclusions Nodule volume by semi-automatic software allowed stratification of LC risk across Lung-RADS v1.1 categories.
Personalized screening algorithm by increased interval seems feasible in 80% of NLST eligible.
Key Points
•Using semi-automatic segmentation of nodule volume, Lung-RADS v1.1 selected 10.8% of subjects with positive CT and 96.87
relative risk of lung cancer at 1 year, compared to negative CT.
•Negative low-dose CT by Lung-RADS v1.1 was found in 80.6% of NLST eligible and yielded 40 times lower relative risk of lung
cancer at 2 years, compared to positive low-dose CT; annual screening could be preference sensitive in this group.
• Semi-automatic segmentation of nodule volume and increased screening interval by volumetric Lung-RADS v1.1 could
retrospectively suggest a 25.5–41% reduction of LDCT burden, at the cost of 13.6–21.9% rate of delayed diagnosis.
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Introduction
Lung cancer screening (LCS) by low-dose computed tomog-
raphy (LDCT) allows for early diagnosis of lung cancer (LC),
resulting in a significant reduction of LC mortality [1–4].
Most trials, including the National Lung Screening Trial
(NLST), applied annual screening frequency, which was de-
rived from modelling analysis [5, 6].
The efficiency of annual screening depends on an individ-
ual risk of LC, which varies substantially even among subjects
with risk factors. In one analysis of NLST population,
Kovalchik et al showed that the number needed to screen
increased by 60-fold for the lowest risk quintile compared
with that for the highest risk quintile [7]. The efficiency of
annual screening scans was substantially reduced in the
lowest-risk subgroup. To improve cost-effectiveness, a
Canadian cost-effectiveness modelling study [8] and post
hoc analysis of NLST data [9, 10] suggested to increase
screening interval after negative LDCT. Two positive
European trials showed reduction of LC mortality by proto-
cols that used longer screening intervals and nodule
volumetry, but had populations with lower risk than NLST
[2, 3].
To date, studies addressing LC risk by LDCT result in
NLST eligible are based on linear measurement of nodule
diameter [6]. Nodule characteristics were the strongest predic-
tors of LC in several retrospective analyses in NLST popula-
tion [9, 10], thus representing an option for systematic im-
provement of screening efficiency. Risk stratification might
vary between linear measurements and nodule volumetry,
especially when different definitions of diameters are applied
(e.g. mean diameter or maximum diameter) [11]. Nodule
volumetry is deemed the most accurate predictor of LC risk
[12], and it is proposed by updated quality assurance initia-
tives and guidelines, for both optimal baseline classification
and longitudinal characterization of growth (e.g. volume dou-
bling time) [13–19].
The linear algorithm of the American College of Radiology
(ACR) Lung CT Screening Reporting & Data System (Lung-
RADS) [20] was updated in 2019 to include conversion of
diameter into volume of a sphere (version 1.1) [21]. The dis-
tribution and LC risk of Lung-RADS v1.1 categories by semi-
automatic nodule volume is not published in the peer review
literature. Also, it is unknown whether these categories might
allow for post-test risk stratification for referral to longer in-
tervals between screening rounds.
The aims of this study were to report the distribution of
Lung-RADS v1.1 volumetric categories in a population of
NLST-eligible subjects and to analyse LC outcomes within
3 years for exploring personalized algorithm for LCS.
Materials and methods
The Multicentric Italian Lung Detection (MILD) study was a
prospective randomized controlled LCS trial launched in 2005
(ethics committee approval INT 53/05; ClinicalTrials.gov
NCT02837809). Informed consent was obtained from
eligible subjects before participation in the MILD study. The
sponsors had no role in conducting and interpreting the study
[22].
MILD eligibility criteria were as follows: age > 49 years,
smoking history ≥ 20 pack-years, current or former smoker
with smoking cessation within 10 years prior to study enrol-
ment and no oncologic history in 5 years before recruitment.
The overall population of MILD study included 4099 partic-
ipants, with 2376 subjects in the intervention arm (median age
58 years, median 39 pack-years, men 68%) [23]. MILD study
population showed a relatively lower-risk profile than the
NLST population, as a consequence of lower threshold in
age and smoking eligibility criteria [1]. In this study, we ex-
tracted a higher-risk population from the MILD study by ap-
plying the NLST eligibility criteria to the intervention arm:
age ≥ 55 years and pack-years ≥ 30 [1]. Fifty-three percent
(1248/2376) of MILD subjects were NLST eligible.
Selected pre-test metrics were gender, smoking status, per-
centage of predicted forced expiratory volume in 1 s
(FEV1%pred, with threshold at 0.9) and the ratio between
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forced expiratory volume in 1 s and forced vital capacity
(FEV1/FVC, with threshold at 0.7) [24].
Baseline LDCT result was defined as follows.
Baseline LDCT result
Baseline LDCT results of the 1248 NLST-eligible subjects
were retrospectively analysed by an advanced workstation
for LCS (CIRRUS Lung Screening), featuring computer-
aided detection (CAD) and semi-automated segmentation for
direct measurement of nodule volume, for both solid and
subsolid nodules. All CAD marks were jointly reviewed by
two experienced thoracic radiologists (8 years and 11 years of
experience in LC screening, each with > 10.000 LDCTs) [25].
The segmentation of nodule volume was checked and adjust-
ed, if necessary, using semi-automatic parameter tuning (den-
sity threshold and irregularity metrics; manual contouring not
allowed). The segmented total nodule volume and volume of
the solid component of a part-solid nodule were used for the
present study.
Volumetric thresholds were applied at baseline LDCT ac-
cording to Lung-RADS v1.1, and management suggestions
were used to establish three major categories of baseline
LDCT result:
– Negative (categories 1 and 2: annual screening
suggested): no nodule, solid or part-solid nodule with
whole volume < 113 mm3 (diameter 6 mm), or non-
solid nodule < 14,137 mm3 (diameter 30 mm)
– Indeterminate (category 3: 6-month LDCT suggested):
solid nodule 113–268 mm3 (diameter 6–8 mm), part-
solid nodule with whole volume ≥ 113 mm3 and solid
component < 113 mm3, or non-solid nodule ≥ 14,137
mm3 (diameter 30 mm)
– Positive (categories 4A and 4B: early recall or work-up):
solid nodule > 268 mm3 or part-solid nodule with solid
component ≥ 113 mm3
Statistical analyses
The distribution of each variable was described in the whole
population and, according to the diagnosis of LC, at each pre-
defined time interval. Frequencies were reported as
percentage.
The primary outcome was the number of LC diagnosed
within 1 year, 2 years and 3 years after baseline. The second-
ary outcome was the stage of LC. The outcomes were collect-
ed during the MILD trial, which included systematic prospec-
tive registration of LC stage, type of resection and histology.
In this analysis, the cumulative frequency of LC was cal-
culated at the three pre-defined time intervals. The cumulative
frequency of LCwas tested against pre-test metrics or baseline
LDCT result. The relative risk (RR) was calculated by the
ratio between the risks of LC in each LDCT group for each
parameter, at each time interval. The RR of pre-test parame-
ters was calculated using the category at lower risk as refer-
ence. The RR of indeterminate and positive LDCT results was
calculated using negative LDCT result as reference.
Kaplan-Meier curves were used to test the probability of
LC for each time interval by unadjusted hazard ratio (HR).
The odds ratio (OR) by univariate and multivariable models
was calculated at each time interval.
The reduction of LDCT burden was calculated by simula-
tion of 4 screening algorithms for increased round interval by
post-test risk stratification with volumetric nodule categories
of Lung-RADS v1.1 (Table 1). The simulated algorithms
stemmed from the annual algorithm of Lung-RADS v1.1
and were developed to encompass the following:
– Biennial or triennial frequency for negative LDCT
– Six-month recall or annual recall for indeterminate
LDCT
Positive LDCT was always intended for short-term recall
within 3 months.
An ideal 100% adherence was assumed throughout the
LCS period, and the recall rate at incidence rounds
was calculated according to the literature (range 3–
14%) [26]. Increasing screening interval is expected to
result in some degree of delayed LC diagnosis; there-
fore, the rate of delayed diagnosis (RDD) was calculat-
ed as follows: ratio between the number of LC diag-
nosed within the proposed interval (6 months or 1 year
for indeterminate, 2 years or 3 years for negative) and
the total number of LC in the full cycle of screening (2
years or 3 years). The proportion of LC in stage I was
calculated for each algorithm at each time interval.
Statistical analysis was performed by Statistical Analysis
System software (version 9.4; SAS Institute) and MedCalc
statistical software (version 17.4; MedCalc Software Bvba).
Results
In the 1248 NLST-eligible subjects (Fig. 1), cumulative LC
frequency was 1.2% at year 1, 1.8% at year 2 and 2.6%
at year 3. Negative LDCT at baseline was seen in 1006
subjects (80.6%; 715 without nodule, 175 with solid
nodule and 116 with non-solid nodule), indeterminate
in 107 subjects (8.6%; 101 with solid nodules and 6
with part-solid nodules) and positive in 135 subjects
(10.8%; 111 with solid nodules and 24 with part-solid
nodules).
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Diagnosis of LC
The probability of LC at years 1, 2 and 3 was higher in sub-
jects with either positive or indeterminate baseline LDCT
(Table 2).
At year 1, 9.6% (13/135) frequency of LC was seen for
positive LDCT, 0.9% (1/107) for indeterminate and 0.1%
(1/1006) for negative; 86.6% (13/15) of LC at year 1 was seen
after a positive LDCT (Fig. 2). The frequency of LC after
negative baseline LDCT remained as low as 0.3% at 2 years
and 0.6% at 3 years.
LDCT result was the strongest predictor of LC through 3
years (Table 2): positive baseline LDCT yielded a RR of
96.87 at year 1, with a progressive decrease through year 2
(RR 39.74) and year 3 (RR 27.32) (Fig. 3). Indeterminate
LDCT was associated with a RR of 9.40 at years 1 and 2,
slightly decreasing to 6.27 at year 3. The HR for LC was
highest in year 1 after positive LDCT and decreased through
years 2 and 3 (Fig. 4).
Univariate analysis of LC risk
Baseline LDCT result was a predictor of LC risk, with greater
magnitude than any pre-test metric (Table 2): analysis at 1-
year interval showed an OR of 102.06 (95% CI 13.49 to
772.19; p < 0.0001) decreasing in analyses at 2-year and 3-
year intervals. Indeterminate LDCT steadily yielded an OR
above 9 at 1-year and 2-year intervals, while decreasing to
6.36 at 3-year interval.
Multivariable analysis of LC risk In multivariable analysis,
baseline LDCT result remained a predictor of LC risk
(Table 3). Positive LDCT showed an OR of 75.60 (95% CI
9.86 to 579.83; p < 0.001) for analysis at 1-year interval and
Fig. 1 The flow diagram details
the selection of high-risk subjects,
classification by nodule volume
in ACR Lung-RADS v1.1 at
baseline low-dose computed to-
mography and relevant cumula-
tive distribution of lung cancer
Table 1 Flow chart detailing the
4 simulations of screening
algorithms with increased round
interval
Negative baseline LDCT Indeterminate baseline LDCT Positive baseline LDCT
Algorithm 1 LDCT in 2 years LDCT in 6 months LDCT in ≤ 3 months
Algorithm 2 LDCT in 2 years LDCT in 1 year LDCT in ≤ 3 months
Algorithm 3 LDCT in 3 years LDCT in 6 months LDCT in ≤ 3 months
Algorithm 4 LDCT in 3 years LDCT in 1 year LDCT in ≤ 3 months
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decreased at 2-year and 3-year intervals. Indeterminate LDCT
yielded a significant OR of 9.16 (95% CI 1.86 to 45.13; p =
0.0068) through a 2-year interval and maintained an OR of
6.35 (95% CI 1.80 to 22.42; p = 0.0042) at 3-year interval.
A selective analysis of risk by pre-test metrics was
performed in the group with negative LDCT: no outstanding
pre-test variable was found for risk stratification (all
p > 0.05, at any time point).
Stage of LC
Stage and histology of LC are detailed by year and LDCT
category in Table 4. After a positive LDCT, 13 LC subjects
were diagnosed in the first year with 30.8% of stage I LC (4
stage I, 2 stage II, 3 stage III, 4 stage IV) and further 9 were
diagnosed in the second and third years with 55.6% stage I LC
(5 stage I and 4 stage IV). Otherwise, early-stage LCwas most
common after negative baseline LDCT (83% stage I and 17%
stage IV) or indeterminate LDCT (75% stage I and 25% stage
II), through the 3 years of this analysis.
Personalized LCS algorithm
The overall RDD ranged from 13.6 to 21.9%, with a rate of
stage I between 75 and 100% among the potentially delayed
LC diagnoses (Table 5). Algorithm 1 (2-year interval for neg-
ative LDCT, 6-month follow-up for indeterminate LDCT)
showed the lowest RDD (13.6%) with the potential 25.5–
26.5% reduction of LDCT over 2 years, compared to annual
benchmark. Algorithm 4 (3-year interval for negative LDCT,
1-year follow-up for indeterminate LDCT) showed not only
the highest potential reduction of LDCT burden (40.6–41%)
but also the highest RDD (21.9%) over 3 years, compared to
annual benchmark.
Discussion
Nodule volume by semi-automatic software allowed stratifi-
cation of LC risk across Lung-RADS v1.1 categories. This
method classified 80.6% negative LDCTwith 0.1% frequency
of LC at 1 year, notably 10 times lower than the mean risk of
LC in NLST eligible. Multivariable analysis showed that nod-
ule volume outstands as a risk factor above pre-test metrics,
especially for stratification of 1-year risk of LC. The proposed
algorithms for increased interval screening showed a potential
25.5–41% reduction of LDCT burden, at the risk of 13.6–
21.9% RDD.
To the best of our knowledge, this is the first analysis of
Lung-RADS v1.1 us ing semi-automat ic volume
measurement.
Post-test risk by Lung-RADS v1.1
The population of this study was retrospectively selected by
NLST criteria, and indeed, the frequency of LC was compa-
rable to original NLST results at year 1 (1.2% here vs 1.0%
NLST), year 2 (1.8% vs 1.8%) and year 3 (2.6% vs 2.7%) [1].
The proportion of nodule categories and their LC risk esti-
mated in the latest Lung-RADS v1.1 are different from the
values measured in this study. The Lung-RADS v1.1 estimat-
ed 90% frequency of categories 1 and 2 with < 1% probability
of LC in 1 year [21]. We measured the 80.6% frequency for
categories 1 and 2, with as low as 0.1% risk of LC at year 1.
Furthermore, we included also measurement of risk at year 2
(0.3%) and year 3 (0.6%). Caverly et al [27] reported that LC
risk ≤ 0.3% would make LCS a preference-sensitive practice.
Fig. 3 Time-resolved relative risk (RR) for lung cancer, according to the
baseline LDCT result
Fig. 2 Relative distribution of LDCT result and LC diagnosis at 1 year, 2
years and 3 years
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This practice was endorsed by Robbins et al [28] in a retro-
spective analysis of NSLT data by diameter classification. Our
study displays that a 0.3% risk is found 2 years after negative
LDCT, suggesting that biennial screening might be proposed
after negative baseline LDCT by Lung-RADS v1.1. This per-
sonalized approach might be assisted by counselling for deci-
sion aid and continuous individualized risk assessment (pre-
test and post-test risks) [29, 30].
The Lung-RADS v1.1 estimated a 5% frequency of cate-
gory 3, with 1–2% probability of LC. We measured the 8.6%
frequency of category 3 with a 0.9% risk of LC in year 1. A
single cancer in this category was diagnosed at 10 months,
which is consistent with the 6-month recall proposed by
Lung-RADS v1.1. The 6-month recall should be preferred
over shorter follow-up (e.g. 3 months) [31] because the rela-
tively small volume of this category is prone to low accuracy
in short-term volumetry for assessment of actual growth [32].
The Lung-RADS v1.1 estimated the 4% frequency of cat-
egory 4, whereas we measured the 10.8% frequency of this
category. Such discrepancy might be accountable to the direct
measurement of nodule volume by semi-automatic software
as opposed to the theoretical conversion of diameter into geo-
metrical sphere. We found a 9.6% risk of LC in category 4
compared with the expected > 5% reported in Lung-RADS
v1.1. Baseline nodule volume by semi-automatic
segmentation allowed remarkable post-test risk stratification
in year 1, with a RR of 96.87 for category 4 compared with
category 1 or 2.
The negative predictive value of Lung-RADS v1.1 in our
selection was comparable to the 2-year performance of the
NELSON volumetric protocol [33]. However, the 268 mm3
positive threshold of Lung-RADS v1.1 likely predicated a
lower positive predictive value compared with that of the
NELSON protocol (500 mm3 threshold at baseline and sub-
sequent characterization by volume doubling time) [34, 35].
The geometrical volumetric threshold of Lung-RADS v1.1
could be further developed by comparison with NELSON
reference, which is based on the direct measurement of nodule
volume by semi-automatic software and is currently validated
in over 10 years of follow-up [36]. It is anticipated that future
studies will test a blend of Lung-RADS v1.1 category and
volume doubling time to improve its accuracy.
Simulation of increased screening interval
The standard of reference from NLST showed that efficiency
of annual screening is variable even among subjects at high
risk [7], for whom increased screening interval might be hy-
pothesized in selected cases. Post hoc analysis of the NLST
dataset brought a wealth of data for optimization of LCS
Fig. 4 Kaplan-Meier curve for
diagnosis of LC through 3 years,
according to the baseline LDCT
result. The bottom section shows
the HR by each pre-defined time
point analysis of LC probability
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algorithm [37], notably increased diameter thresholds [37]
(featured in Lung-RADS v1.0) and evidence of safe feasibility
of biennial screening [9, 10]. Patz et al [9] retrospectively
modelled biennial screening with a 0.48% frequency of LC
in 2 years after negative baseline LDCT by linear measure-
ment (< 4 mm). The same authors also reported a 1.1% fre-
quency of LC in 3 years after negative baseline LDCT. Our
results show that a semi-automatic volume in category 1 or 2
of Lung-RADS v1.1 (e.g. negative LDCT result) selects even
a lower frequency of LC (0.3% at 2 years and 0.6% at 3 years).
These figures came along with the 80.6% of population with
negative baseline LDCT, which points to a potentially remark-
able reduction of LDCT burden by longer-than-annual screen-
ing interval. With this purpose, we simulated several scenarios
of increased screening interval and compared these with the
reference standard of annual screening by Lung-RADS v1.1.
The proposed algorithms showed a reduction of LDCT
burden ranging from 25 to 41% through years 2 and 3,
reflecting a potential-paralleled reduction in both costs and
cumulative radiation burden. Our biennial simulation is
aligned with the prospective results from the interval random-
ization of MILD, which showed an overall 38% reduction of
LDCT burden in the biennial arm, without detrimental effect
[38]. The biennial strategy might also help with the growing
demand of capacity for steadily increasing utilization of LCS
[39]. Biennial follow-up is endorsed by the National Health
Service (NHS) England in their protocol for implementation
of targeted lung health check programme at population level
Table 3 Multivariate analysis of risk of LC diagnosis at 1 year, 2 years and 3 years, according to the pre-test metrics and baseline LDCT result
1 year 2 years 3 years
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Pre-test metrics
Gender*
Female ref ref ref
Male N.A. – 2.89 (0.67–12.38) 0.1560 2.04 (0.71–5.88) 0.1629
Smoking status
Former ref ref ref
Current 1.55 (0.49–4.93) 0.4623 1.19 (0.48–2.95) 0.7155 1.56 (0.69–3.53) 0.2884
FEV1%pred
> 90% ref ref ref
≤ 90% 3.29 (0.82–13.23) 0.0958 2.37 (0.84–6.68) 0.1039 1.77 (0.76–4.10) 0.1866
FEV1/FVC
> 70% ref ref ref
≤ 70% 2.06 (0.62–6.81) 0.2407 2.27 (0.86–5.99) 0.0982 2.74 (1.20–6.23) 0.0042
Baseline LDCT result
Negative ref Ref ref
Indeterminate 7.90 (0.50–125.03) 0.1445 9.16 (1.86–45.13) 0.0068 6.35 (1.80–22.42) 0.0042
Positive 75.60 (9.86–579.83) < 0.0001 31.01 (8.93–107.62) < 0.0001 21.36 (8.49–53.79) < 0.0001
OR odds ratio, CI confidence interval
*OR could not be calculated because of the absence of LC in one category of the selected metric
Table 4 Distribution of the stage and histology of LC through the 3-year interval, according to the baseline LDCT result
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Stage Histology
I II III IV I II III IV I II III IV ADC SCC SCLC Other ADC SCC SCLC Other ADC SCC SCLC Other
Negative 1 – – – 2 – – – 2 – – 1 1 – – – 1 1 – – 2 1 – –
Indeterminate – 1 – – 2 – – – 1 – – – 1 – – – 2 – – – 1 – – –
Positive 4 2 3 4 2 – – 1 3 – – 3 5 5 – 3 2 1 – – 4 – – 2
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[40]. The NHS England proposed a reference volume < 80
mm3 for biennial follow-up of solid nodules, which is smaller
than the < 113 mm3 reference analysed in our paper.
Noteworthy, the performance of either threshold might vary
significantly depending on the software for semi-automatic
segmentation of volume [41].
Otherwise, the triennial simulations appeared quite hazard-
ous because they were associated with up to 21.9% delayed
diagnosis, with potential overlooking of a substantial propor-
tion of stage I LC. Despite this figure is quite close to the
frequency of overdiagnosis modelled on the NLST data
[42], however, we cannot assume such overlapping. A
NELSON report showed that a 2.5-year interval is associated
with a significant increase of interval cancer and substantial
stage shift [43]. We confirm that LDCT result alone does not
allow safe selection for triennial screening interval.
Complementary approach to LCS by integrating biological
risk stratification might allow safe application of biennial or
triennial screening interval [44]. Algorithm 4 of this paper was
prospectively tested in the bioMILD trial (NCT02247453)
where triennial LDCT was proposed along with personalized
risk stratification by microRNA signature classifier (MSC).
The bioMILD trial started in 2013 (4119 subjects, 50–75
years, ≥ 30 pack-years), with a semi-automatic segmentation
of nodule and volumetric thresholds closely overlapping the
most recent Lung-RADS v1.1. The preliminary results of
bioMILD trial reported that the personalized interval of LCS
every 3 years is safe when both semi-automatic nodule vol-
ume and MSC render negative result at baseline [45].
This study has some limitations. We grouped Lung-RADS
category 4 under the definition of positive LDCT result and
did not detail the granularity of categories 4A, 4B and 4X. We
did not assess nodule-specific cancer rate but measured
subject-specific cancer rate; this approach was intended to
better serve in screening practice. The small population might
have hindered a significant association of pre-test metrics with
a risk of LC; nonetheless, it could show robust post-test risk
stratification by Lung-RADS v1.1. The retrospective nature of
this study hampers the actual estimation of stage shift and
interval cancers [43]. Nonetheless, such a retrospective ap-
proach provided a picture of the nodule distribution under
cutting-edge technological conditions for semi-automatic
nodule volume and recently updated Lung-RADS v1.1. The
present study did not account for further imaging findings
(e.g. emphysema, interstitial lung abnormalities, pleural
plaques), which might confer an additional post-test risk be-
yond nodule [40, 46–49]. Finally, the proposed algorithms
might result in different outcomes when applied out of the
present population and methods (e.g. volume LDCT analysed
by CAD); therefore, caution is granted before application of
these findings. The number of LC is quite low in groups with
negative or intermediate LDCT, and this figure should be
carefully interpreted because different absolute values might
be observed in other settings. Prospective trials are needed to
test whether the trade-off of longer screening intervals after
negative LDCT will lead to a reduction in the number of lung
cancer deaths avoided [50, 51].
In conclusion, this study represents the first analysis of
Lung-RADS v1.1 category distribution using semi-
automatic software for segmentation of nodule volume on
thin-slice LDCT. This volumetric approach led to personal-
ized stratification of LC risk among NLST-eligible subjects,
and notably, the risk of LC in Lung-RADS v1.1 category 1 or
2 was substantially lower than that in category 3. Lung-RADS
v1.1 categories showed that potential for longer than 1-year
screening interval in up to 80% of NLST-eligible subjects.
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